Forecast

The analysts' average price target is +2,74€ (−1,44%). The median is +2,71€ (−2,52%).

Buy	8
Hold	15
Sell	2

News Go to news feed

ARCHIMED buys Esperion for up to $1.1 billion

ARCHIMED funds have signed a takeover agreement for Esperion that values the company at up to about $1.1 billion. Shareholders will receive $3.16 in cash per share plus non-tradable milestone rights (CVR) of up to $100 million, tied to future U.S. net revenues of certain products. The cash payment represents a 58% premium to the April 30, 2026 closing price; the Esperion share currently trades well below the offer price. The board recommends acceptance, closing is expected in Q3 2026; after the acquisition Esperion will be taken private and its stock will be removed from NASDAQ. » More on de.investing.com
Esperion sells Japan license rights to Athyrium for $50 million

Esperion sold funds from Athyrium the claim on tiered royalties for Otsuka’s bempedoic acid products in Japan for $50 million. Athyrium will receive, starting January 1, 2026, tiered royalties of 12–33% plus milestone payments until it recoups 2.0× its investment, after which the rights revert to Esperion. Esperion plans to use the proceeds to finance the acquisition of Corstasis Therapeutics, which markets the approved bumetanide nasal spray Enbumyst. » More on de.investing.com
Esperion reports strong revenue growth and acquires Corstasis

Esperion recorded total revenue of $408 million in 2025 (+38%) and a 34% increase in prescriptions. The company announced the acquisition of Corstasis Biotherapeutics, including the nasal loop diuretic Enbumyst, with closing expected in early April. International partnerships with Daiichi Sankyo and Otsuka and the "Vision 2040" strategy are intended to further expand the bempedoic acid franchise and the ACLY pipeline. Esperion ended 2025 with $168 million in cash and expects 2026 to be its most successful year to date. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Esperion Therapeutic. Inc. has already paid 2,78€ in dividends. The last payout was in July.

Financials

In the last quarter, Esperion Therapeutic. Inc. had revenue of 69,20M€ and net profit of −21,77M€

(EUR)	Mar 2026	YoY
Revenue	+69,20M	15,19%
Gross profit	+39,33M	27,19%
Net profit	−21,77M	41,79%
EBITDA	−38,85M	100,14%

Fundamentals

Metric	Value
Market capitalization	+567,26M€
Number of shares	207,91M
52-week high/low	+3,58€ - +0,97€
Dividend yield	+99,86%
Dividends TTM	+2,78€
Beta	1,06
P/E ratio	−131,40
PEG ratio	−0,40
P/B ratio	−2,60
P/S ratio	+1,58

Company profile

Esperion Therapeutics, Inc. ist ein pharmazeutisches Unternehmen, das Medikamente zur Behandlung von Patienten mit erhöhtem Lipoprotein niedriger Dichte entwickelt und vermarktet. Die führenden Produktkandidaten sind NEXLETOL (Bempedosäure) und NEXLIZET (Bempedosäure und Ezetimib) Tabletten für die Behandlung von Patienten mit atherosklerotischen Herz-Kreislauf-Erkrankungen oder heterozygoter familiärer Hypercholesterinämie. Das Unternehmen hat eine Lizenz- und Kooperationsvereinbarung mit Daiichi Sankyo Europe GmbH und Serometrix zur Einlizenzierung seines oralen, niedermolekularen PCSK9-Inhibitorprogramms geschlossen. Esperion Therapeutics, Inc. wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in Ann Arbor, Michigan.

Name	Esperion Therapeutic. Inc.
CEO	Sheldon L. Koenig
Headquarters	Ann Arbor, mi USA
Website	esperion.com
Sector	Materials
Industry	Chemicals
IPO	06/26/2013
Employees	294